Suzhou Neuralstem Biopharmaceutical

Suzhou Neuralstem Biopharmaceutical is a biotechnology company based in Suzhou, China, specializing in the development of regenerative medicine therapies for central nervous system disorders. Originally established as the Chinese subsidiary or joint venture of the U.S.-based Neuralstem (now Palisade Bio), the company focuses on advancing clinical trials within the Chinese market. Its primary candidate, NSI-566, is a human spinal cord-derived neural stem cell line currently being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS), stroke, and spinal cord injury. The company utilizes a proprietary technology that allows for the commercial-scale production of stable, regional-specific neural stem cells. Suzhou Neuralstem plays a critical role in bridging Western regenerative technologies with the clinical and regulatory landscape in China.